Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials

Open Access

Peer-reviewed

Research Article

Li Cao ,

Contributed equally to this work with: Li Cao, Guang-yu Yao

Affiliation Breast Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
⨯
Guang-yu Yao ,

Contributed equally to this work with: Li Cao, Guang-yu Yao

Affiliation Breast Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
⨯
Min-feng Liu,

Affiliation Breast Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
⨯
Lu-jia Chen,

Affiliation Breast Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
⨯
Xiao-lei Hu,

Affiliation Breast Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
⨯
Chang-sheng Ye

* E-mail: yechangsheng2015@126.com

Affiliation Breast Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
⨯

Reader Comments (0)

Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Randomized controlled trials
Is the Subject Area "Randomized controlled trials" applicable to this article?

Thanks for your feedback.
Cancer chemotherapy
Is the Subject Area "Cancer chemotherapy" applicable to this article?

Thanks for your feedback.
Toxicity
Is the Subject Area "Toxicity" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.
Surgical and invasive medical procedures
Is the Subject Area "Surgical and invasive medical procedures" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Chemotherapy
Is the Subject Area "Chemotherapy" applicable to this article?

Thanks for your feedback.